Arcutis Biotherapeutics (ARQT) officer sells 684 shares to cover RSU taxes

Rhea-AI Filing Summary

Arcutis Biotherapeutics insider files Form 4 for a small tax-related sale. Officer Patrick Burnett sold 684 shares of common stock on May 4, 2026 at a weighted average price of $23.6106 per share. The footnotes state the sale was made solely to cover tax withholding obligations from vesting Restricted Stock Units. After this transaction, Burnett directly holds 120,466 shares of Arcutis common stock.

Insider Trade Summary 10b5-1

Net Seller: 684 shares ($16,150)

Net Sell 1 txn

Insider Burnett Patrick

Role See Remarks

Sold 684 shs ($16K)

Type	Security	Shares	Price	Value
Sale	Common Stock	684	$23.6106	$16K

Holdings After Transaction: Common Stock — 120,466 shares (Direct, null)

Footnotes (1)

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.16 to $23.93, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Key Figures

Shares sold: 684 shares Weighted average sale price: $23.6106 per share Ownership after transaction: 120,466 shares +1 more

4 metrics

Shares sold 684 shares Open-market sale on May 4, 2026

Weighted average sale price $23.6106 per share Common stock sale on May 4, 2026

Ownership after transaction 120,466 shares Directly owned by Patrick Burnett after sale

Sale price range $23.16 to $23.93 Multiple trades within this range per footnote

Key Terms

Restricted Stock Units, weighted average sale price, tax withholding obligations, open-market sale

4 terms

Restricted Stock Units financial

"in connection with the vesting of Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The price reported in Column 4 is a weighted average sale price."

tax withholding obligations financial

"shares sold by the Reporting Person to cover tax withholding obligations"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burnett Patrick

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CALIFORNIA 91361

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/04/2026		S(1)		684	D	$23.6106(2)	120,466	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.16 to $23.93, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

Reporting Person's Title: EVP, Chief Medical Officer

	/s/ Latha Vairavan, as Attorney-in-Fact for Patrick Burnett	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Arcutis Biotherapeutics (ARQT) insider Patrick Burnett report on this Form 4?

Patrick Burnett reported selling 684 shares of Arcutis Biotherapeutics common stock. The transaction occurred on May 4, 2026 and is classified as an open-market sale, according to the filing’s transaction code and description.

Why did Arcutis Biotherapeutics (ARQT) officer Patrick Burnett sell 684 shares?

The filing explains the 684-share sale was made to cover tax withholding obligations. These obligations arose in connection with the vesting of Restricted Stock Units, making the sale a tax-related event rather than a discretionary portfolio decision.

At what price were the 684 Arcutis Biotherapeutics (ARQT) shares sold on May 4, 2026?

The shares were sold at a weighted average price of $23.6106 per share. A footnote notes multiple transactions between $23.16 and $23.93, and the insider offers to provide detailed trade breakdowns upon request to regulators or shareholders.

How many Arcutis Biotherapeutics (ARQT) shares does Patrick Burnett own after this Form 4 transaction?

Following the reported sale, Patrick Burnett directly owns 120,466 shares of Arcutis Biotherapeutics common stock. This remaining position indicates the 684-share sale was small relative to his overall holdings disclosed in the filing.

Was the Arcutis Biotherapeutics (ARQT) insider sale part of a trading plan?

The provided Form 4 excerpt does not mention any Rule 10b5-1 or similar pre-arranged trading plan. The only stated reason for the transaction is covering tax withholding obligations from vesting Restricted Stock Units.